Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VTVT vs TLPH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TLPH Captures Overall Composite Edge (37.1 SELL vs 39.2 SELL), While VTVT Leads 4–1 on Growth & Valuation Pillars

TLPH Overall Winner 6-Pillar Tally: VTVT 4 – 1 TLPH (1 Tie) Matrix Metrics: VTVT 5 – 4 TLPH

As of Nov 16, 2026, Talphera, Inc. (TLPH) captures the overall head-to-head institutional edge over vTv Therapeutics Inc. (VTVT) on higher Unified Composite conviction (37.1/100 SELL vs. 39.2/100 SELL) after splitting the core matrix 4–5 (led by Valuation Multiples), while VTVT wins 4–1 across the 6-pillar growth and valuation breakdown. VTVT trades at $17.62 (N/M Forward P/E, -29.8% operating margin) versus TLPH at $0.86 (1.0x Forward P/E, -1474700.0% operating margin).

  • Composite vs. Pillar Nuance: While VTVT currently prints a higher short-term Unified Composite Score (39.2/100 SELL vs. TLPH 37.1/100 SELL), TLPH captures the overall institutional head-to-head verdict (4–5 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-1474700.0% vs. -29.8% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Defensive Composite Rating Caution: Although TLPH compares more favorably head-to-head, both VTVT (39.2/100 SELL) and TLPH (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: VTVT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 19.7); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VTVT vs TLPH
VTVT NASDAQ
vTv Therapeutics Inc. Class A Common Stock
Pharmaceutical Preparations
$17.62
-10.51% 1D
Market Cap $78.3M
TTM Revenue $37M
Forward P/E N/M
Beta / 30D Vol 1.48β · 53% Vol
Unified Composite Score
39.2 / 100 SELL
Tech 25.0 Fund 44.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.4%), weak momentum, RSI 20
RSI-14: 19.7 · SMA20: $23.70 · SMA50: $27.74
TLPH NASDAQ Head-to-Head Winner
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10

6-Pillar Scorecard Institutional Category Breakdown (VTVT 4 – 1 TLPH)

Columns: Metric · VTVT · TLPH
1. Valuation Multiples TLPH
Forward P/E N/M 1.0x
Trailing P/E N/M 1.0x
PEG Ratio N/M N/M
EV / Revenue 2.1x N/M
2. Growth & Scale VTVT
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $37M $1,000
Market Cap $78.3M $53.7M
3. Profitability & Quality VTVT
Gross Margin 51.5% N/A
Operating Margin -29.8% -1474700.0%
Net Profit Margin -20.8% 0.0%
Return on Equity (ROE) -10.9% -143.4%
4. Balance Sheet & Cash Flow VTVT
Cash Generation (TTM) -$11M EBITDA -$15M EBITDA
Cash Flow Margin -29.8% EBITDA Mgn N/A
Net Cash / Leverage $5.61 Book/Sh · -10.9% ROE $0.28 Book/Sh · -143.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 118.4% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat VTVT
OpEx & R&D Intensity 81.3% of Rev ($30M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VTVT (5) vs TLPH (4)
Institutional Metric VTVT TLPH Criterion Row Edge
Market Capitalization
Scale
$78.3M $53.7M Larger Scale VTVT
Trailing P/E Ratio
Valuation
N/M 1.0x Lower Multiple TLPH
Forward P/E Ratio
Valuation
N/M 1.0x Lower Multiple TLPH
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
-29.8% -1474700.0% Higher Margin VTVT
Net Profit Margin
Profitability
-20.8% 0.0% Higher Margin TLPH
Return on Equity (ROE)
Capital Efficiency
-10.9% -143.4% Higher ROE VTVT
52-Week Range Position
Momentum
1% ($17–$44) 20% ($1–$2) Stronger Trend TLPH
Beta / 30D Volatility
Risk Regime
1.48β · 53% Vol 1.11β · 58% Vol Lower Realized Risk VTVT
Unified Institutional Score
Composite Signal
39.2 / 100 (SELL) 37.1 / 100 (SELL) Higher Composite VTVT
Trailing 12M Revenue (USD)
Operating Scale
$37M $1,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
51.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA ($5.61 Book/Sh · -10.9% ROE) -$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TLPH +13.32 pp
VTVT: -33.61% · TLPH: -20.29%
3M Horizon TLPH +15.18 pp
VTVT: -44.03% · TLPH: -28.85%
6M Horizon TLPH +58.33 pp
VTVT: -50.35% · TLPH: +7.98%
1Y Horizon TLPH +25.64 pp
VTVT: -43.65% · TLPH: -18.01%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VTVT vs TLPH. Trailing 12-month operating profitability (VTVT -29.8% vs TLPH -1474700.0%) and valuation multiples (VTVT N/M vs TLPH 1.0x Forward P/E) are benchmarked directly in Pillar 4 below.

VTVT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$37M
Gross Margin51.5%
Op. Margin-29.8%
ROE / Fwd P/E-10.9% · N/M
TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VTVT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTVT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VTVT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $78.3M market capitalization and -29.8% operating margin.
OpEx & R&D Reinvestment 81.3% of Rev ($30M)
90D Engineering Disclosures 0 Published
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VTVT vs TLPH Key Questions & Quantitative Answers

As of Nov 16, 2026, Talphera, Inc. (TLPH) captures the overall head-to-head institutional edge over vTv Therapeutics Inc. (VTVT) on higher Unified Composite conviction (37.1/100 SELL vs. 39.2/100 SELL) after splitting the core matrix 4–5 (led by Valuation Multiples), while VTVT wins 4–1 across the 6-pillar growth and valuation breakdown. VTVT trades at $17.62 (N/M Forward P/E, -29.8% operating margin) versus TLPH at $0.86 (1.0x Forward P/E, -1474700.0% operating margin). Composite vs. Pillar Nuance: While VTVT currently prints a higher short-term Unified Composite Score (39.2/100 SELL vs. TLPH 37.1/100 SELL), TLPH captures the overall institutional head-to-head verdict (4–5 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-1474700.0% vs. -29.8% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Defensive Composite Rating Caution: Although TLPH compares more favorably head-to-head, both VTVT (39.2/100 SELL) and TLPH (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: VTVT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 19.7); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VTVT leads the Growth & Scale pillar: VTVT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $37M TTM revenue (51.5% gross margin, -29.8% operating margin), compared with TLPH at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin). On trailing 12-month operating scale, VTVT generates $37M in USD-normalized revenue versus $1,000 for TLPH. In operating R&D and SG&A reinvestment, VTVT deploys 81.3% of Rev ($30M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TLPH.

TLPH screens cheaper on headline valuation multiples. VTVT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.1x EV/Revenue (-29.8% EBITDA margin), whereas TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTVT (-10.9% ROE) versus TLPH (-143.4% ROE) capital efficiency.

In options market volatility and institutional positioning, VTVT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.48β · 53% Vol realized risk). By comparison, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.